Inhibitors of hepatitis c virus

An alkyl and cycloalkyl technology, applied in the field of antiviral compounds, can solve the problem that the viral load does not continue to decrease

Inactive Publication Date: 2009-11-18
BRISTOL MYERS SQUIBB CO
View PDF20 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, even with an experimental treatment regimen that included a combination of pegylated interferon-alpha and ribavirin, a significant proportion of patients did not experience sustained reductions in viral load

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhibitors of hepatitis c virus
  • Inhibitors of hepatitis c virus
  • Inhibitors of hepatitis c virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0177] Racemic ethyl (1R,2S) / (1S,2R)-1-amino-2-vinylcyclopropanecarboxylate hydrochloride Preparation (Method A and Method B)

[0178]

[0179] The compound was racemized by each of the following methods A and B.

[0180] Method A

[0181] Preparation of N-benzyl imine of ethyl glycine

[0182]

[0183] Glycine ethyl ester hydrochloride (303.8 g, 2.16 mol) was suspended in tert-butyl methyl ether (1.6 L). Benzaldehyde (231 g, 2.16 mol) and anhydrous sodium sulfate (154.6 g, 1.09 mol) were added and the mixture was cooled to 0°C using an ice water bath. Triethylamine (455 mL, 3.26 mol) was added dropwise over 30 minutes, and the mixture was stirred at room temperature for 48 hours. The reaction was then quenched by adding ice-cold water (1 L) and the organic layer was separated. The aqueous phase was extracted with tert-butyl methyl ether (0.5 L), and the combined organic phases were washed with a mixture of saturated aqueous NaHCO3 (1 L) and brine (1 L). The s...

Embodiment 2

[0195] Resolution of N-Boc-(1R, 2S) / (1S, 2R)-1-amino-2-vinylcyclopropanecarboxylic acid ethyl ester

[0196]

[0197] Racemates: (1R, 2S) and (1S, 2R)

[0198] 1:1 mixture of

[0199] Split A

[0200] To an aqueous solution of sodium phosphate buffer (0.1 M, 4.25 liters (“L”), pH 8) in a 12-liter jacketed reactor maintained at 39° C. and stirred at 300 rpm was added 511 grams of Alcalase 2.4 L (approx. 425 ml) (Novozymes North America Inc.). When the temperature of the mixture reached 39°C, the pH was adjusted to 8.0 by adding 50% NaOH in water. A solution of racemic ethyl N-Boc-(1R,2S) / (1S,2R)-1-amino-2-vinylcyclopropanecarboxylate (85 g) in 850 mL DMSO was then added over 40 minutes. The reaction temperature was then maintained at 40°C for 24.5 hours, during which time the pH of the mixture was adjusted to 8.0 with 50% NaOH in water at the 1.5 and 19.5 hour time points. After 24.5 hours, the enantiomeric excess of the ester was measured to be 97.2%, the reaction ...

Embodiment 3

[0247] Step 1: Preparation of ethyl 1(R)-amino-2(S)-vinylcyclopropanecarboxylate hydrochloride

[0248]

[0249] Ethyl 1(R)-tert-butoxycarbonylamino-2(S)-vinylcyclopropanecarboxylate (8.5 g, 33.3 mmol) was washed with 200 mL of 4N HCl / dioxane ( Aldrich) was stirred at room temperature for 3 hours. The solvent was removed under reduced pressure keeping the temperature below 40 °C. This yielded 6.57 g (-100%) of ethyl 1(R)-amino-2(S)-vinylcyclopropanecarboxylate hydrochloride as a light brown (tan) solid. 1H NMR (300MHz, CD 3 OD) δ1.31(t, J=7.0Hz, 3H), 1.69-1.82(m, 2H), 2.38(q, J=8.8Hz, 1H), 4.29(q, J=7.0Hz, 2H), 5.22 (d, J=10.3Hz, 1H), 5.40 (d, J=17.2Hz, 1H), 5.69-5.81 (m, 1H). MS m / z 156 (M++1).

[0250] Step 2: 1(R)-[1-tert-butoxycarbonyl-4(R)-hydroxypyrrolidine-2(S)-carboxamido Preparation of ethyl (carboxamido)]-2(S)-vinylcyclopropanecarboxylate

[0251]

[0252] With N-methylmorpholine (9.3 mL, 84.7 mmol), HATU (19.5 g, 51.3 mmol) and ethyl 1(R)-amino-2(S...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Macrocyclic peptides are disclosed having the general formula: wherein R3, R3', R4, R6, R', X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of US Provisional Application Serial No. 60 / 863,845, filed November 1, 2006. field of invention [0003] The present disclosure relates generally to antiviral compounds, and more particularly to compounds that inhibit the function of the NS3 protease (also referred to herein as "serine protease") encoded by hepatitis C virus (HCV), compositions comprising such compounds, and compounds that inhibit NS3 Methods of protease function. Background of the invention [0004] HCV is a major human pathogen, infecting an estimated 170 million people worldwide—roughly five times the number infected by human immunodeficiency virus type 1. A significant proportion of these HCV-infected individuals develop severe progressive liver disease, including cirrhosis and hepatocellular carcinoma. [0005] Currently, the most effective HCV therapy employs a combination of alpha-interferon and ribavirin, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D409/04C07D231/56C07D237/32C07D239/88C07D487/04C07D495/04C07D498/04C07K5/08
CPCA61K31/7056C07K5/0804A61K38/21C07D513/04C07K5/0808C12N15/113A61K45/06A61K31/00A61K38/208A61K38/212A61K47/48215C07D487/04A61K38/204A61K38/2013A61K47/60A61P1/16A61P31/12A61P31/14A61K2300/00
Inventor S·丹德里P·M·斯科拉
Owner BRISTOL MYERS SQUIBB CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap